Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
- Interventions
- Drug: HPB-092 tablet
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT07137637
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Not Applicable
Not yet recruiting
- Conditions
- MDSAML
- Interventions
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT07131085
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Not Applicable
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
- Interventions
- Biological: uCD7 CART
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Target Recruit Count
- 12
- Registration Number
- NCT07109518
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Acute LeukemiaALL (Acute B-Lymphoblastic Leukemia)Acute Leukemia RefractoryAcute Myeloid Leukemia (AML)Acute Leukemia in Relapse
- Interventions
- Biological: TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT07087847
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: GB3226
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 184
- Registration Number
- NCT07084584
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)
- Interventions
- Diagnostic Test: 5hmC BiomarkerDrug: Anthracycline
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 112
- Registration Number
- NCT07060001
- Locations
- 🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Oral Cladribine
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT07053020
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Not Applicable
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT07044687
- Locations
- 🇮🇳
LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781, Pune, Maharashtra, India
🇮🇳Sahyadri Super Speciality Hospital /ID# 272074, Pune, Maharashtra, India
🇮🇳Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692, Hyderabad, Telangana, India
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Yehui Tan
- Target Recruit Count
- 70
- Registration Number
- NCT07023588
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
Phase 1
Not yet recruiting
- Conditions
- AML - Acute Myeloid Leukemia
- Interventions
- Drug: Dexamethasone plus Venetoclax-based Low-Intensity Therapy
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 20
- Registration Number
- NCT07014462
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States